Gilad Oren, President and CEO of Aprea Therapeutics, Inc. (NASDAQ:APRE), has recently acquired additional shares in the company, according to a recent SEC filing. On October 10 and October 14, Oren purchased a total of 1,150 shares of common stock. The transactions were executed at prices ranging from $2.54 to $2.59 per share, resulting in a total investment of $2,971.
Following these transactions, Oren's direct ownership increased to 332,645 shares. Additionally, the filing notes indirect holdings of 1,800 shares, attributed to his daughter and son, although Oren disclaims beneficial ownership of these securities.
This move by Oren may reflect confidence in Aprea Therapeutics' prospects, as the company continues to operate within the pharmaceutical preparations sector.
InvestingPro Insights
Gilad Oren's recent share purchases come at a time when Aprea Therapeutics (NASDAQ:APRE) faces significant financial challenges, as revealed by InvestingPro data. The company's market capitalization stands at a modest $13.91 million, reflecting its current position in the pharmaceutical sector.
Despite the CEO's show of confidence, InvestingPro Tips highlight that APRE is "quickly burning through cash" and "suffers from weak gross profit margins." These factors are evident in the company's financial metrics, with a gross profit margin of -552.7% for the last twelve months as of Q2 2024. Additionally, the operating income margin stands at an alarming -1112.69% for the same period.
On a positive note, one InvestingPro Tip indicates that APRE "holds more cash than debt on its balance sheet," which could provide some financial flexibility as the company navigates its current challenges. This aligns with another tip stating that "liquid assets exceed short term obligations," potentially offering a buffer against immediate financial pressures.
The stock's performance has been concerning, with InvestingPro data showing a 6-month price total return of -56.61% as of the latest available data. This decline is consistent with the InvestingPro Tip that the "stock has taken a big hit over the last six months."
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for APRE, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.